The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Capecitabine: A review
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783
Sch�ller, J., Cassidy, J., Dumont, E., Roos, B., Banken, L., Mori, K., Reigner, B., Utoh, M., Weidekamm, E., & Durston, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050043 · Cited by 534
Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf089 · Cited by 425
Sawada, N., Ishikawa, T., Fukase, Y., Nishida, M., Yoshikubo, T., & Ishitsuka, H. (1998) · PubMed · Cited by 422
Cutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 401
Blum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · Cited by 398
Clinical Pharmacokinetics of Capecitabine
Reigner, B., Blesch, K., & Weidekamm, E. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140020-00002 · Cited by 388
Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1337 · Cited by 318
Fumoleau, P., Largillier, R., Clippe, C., Dièras, V., Orfeuvre, H., Lesimple, T., Culine, S., Audhuy, B., Serin, D., Curé, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.007 · Cited by 305
O’Shaughnessy, J. A., Blum, J., Moiseyenko, V., Jones, S. E., Miles, D., Bell, D., Rosso, R., Mauriac, L., Osterwalder, B., Burger, H.-U., et al. (2001) · Annals of Oncology · doi:10.1023/a:1012281104865 · Cited by 304
Mackean, M., Planting, A., Twelves, C., Schellens, J., Allman, D., Osterwalder, B., Reigner, B., Griffin, T., Kaye, S., & Verweij, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2977 · Cited by 264
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Budman, D. R., Meropol, N. J., Reigner, B., Creaven, P. J., Lichtman, S. M., Berghorn, E., Behr, J., Gordon, R. J., Osterwalder, B., & Griffin, T. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1795 · Cited by 261
Reichardt, P., von Minckwitz, G., Thuss-Patience, P. C., Jonat, W., Kölbl, H., Jänicke, F., Kieback, D. G., Kuhn, W., Schindler, A. E., Mohrmann, S., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg346 · Cited by 237
Rich, T. A., Shepard, R. C., & Mosley, S. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.009 · Cited by 212
Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer
Cartwright, T. H., Cohn, A. L., Varkey, J. A., Chen, Y.-M., Szatrowski, T. P., Cox, J. V., & Schulz, J. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.160 · Cited by 201
Scheithauer, W., Schüll, B., Ulrich-Pur, H., Schmid, K., Raderer, M., Haider, K., Kwasny, W., Depisch, D., Schneeweiss, B., Lang, F., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg029 · Cited by 187
Talbot, D. C., Moiseyenko, V, Van Belle, S., O'Reilly, S. M., Alba Conejo, E., Ackland, S., Eisenberg, P., Melnychuk, D., Pienkowski, T., Burger, H.-U., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600261 · Cited by 181
Cardiotoxicity of the Antiproliferative Compound Fluorouracil
Becker, K., Erckenbrecht, J. F., aussinger, D. H., & Frieling, T. (1999) · Drugs · doi:10.2165/00003495-199957040-00003 · Cited by 172
Borner, M. M., Dietrich, D., Stupp, R., Morant, R., Honegger, H., Wernli, M., Herrmann, R., Pestalozzi, B. C., Saletti, P., Hanselmann, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.087 · Cited by 169
Twelves, C., Glynne‐Jones, R., Cassidy, J., Schüller, J., Goggin, T. K., Roos, B., Banken, L., Utoh, M., Weidekamm, E., & Reigner, B. G. (1999) · PubMed · Cited by 155
Bajetta, E., Bartolomeo, M. D., Mariani, L., Cassata, A., Artale, S. A., Frustaci, S., Pinotti, G., Bonetti, A. V., Carreca, I. U., Biasco, G., et al. (2004) · Cancer · doi:10.1002/cncr.11910 · Cited by 137
Poole, C. J., Gardiner, J., Twelves, C. J., Johnston, P., Harper, P., Cassidy, J., Monkhouse, J., Banken, L., Weidekamm, E., & Reigner, B. G. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0408-0 · Cited by 134
Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine
Bollag, W. B., & Hartmann, H. R. (1980) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(80)90221-2 · Cited by 131
Judson, I. R., Beale, P. J., Trigo, J. M., et al. (1999) · Investigational New Drugs · doi:10.1023/a:1006263400888 · Cited by 121
Hess, V., Salzberg, M. O., Borner, M., Morant, R., Roth, A. D., Ludwig, C., & Herrmann, R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.029 · Cited by 95
Cassidy, J., Dirix, L. Y., Bissett, D., et al. (1998) · PubMed · Cited by 87
Gradishar, W. J., Meza, L., Amin, B., Samid, D., Hill, T. R., Chen, Y.-M., Lower, E. E., & Marcom, P. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.128 · Cited by 87
New systemic frontline treatment for metastatic colorectal carcinoma
Braun, A., Achterrath, W., Wilke, H., Vanhoefer, U. J., Harstrick, A., & Preusser, P. (2004) · Cancer · doi:10.1002/cncr.20154 · Cited by 76
Villalona-Calero, M. A., Weiss, G. R., Burris, H. A., Kraynak, M. A., Rodrigues, G., Drengler, R. L., Eckhardt, S. G., Reigner, B. G., Moczygemba, J., Burger, H. U., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1915 · Cited by 71
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
Reigner, B. G., Clive, S., Cassidy, J., et al. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050900 · Cited by 70
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A Phase II trial
Shields, A. F., Zalupski, M. M., Marshall, J. L., & Meropol, N. J. (2004) · Cancer · doi:10.1002/cncr.11925 · Cited by 66
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
Zeuli, M., Nardoni, C., Pino, M. S., Gamucci, T., Gabriele, A., Ferraresi, V., Giannarelli, D., & Cognetti, F. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg360 · Cited by 63
Stathopoulos, G. P., Syrigos, K. N., Polyzos, A., Fountzilas, G., Rigatos, S. K., Ziras, N., Potamiannou, A., Tsiakopoulos, I., Androulakis, N. E. M., Aravantinos, G., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh065 · Cited by 58
Sobrero, A. F., Guglielmi, A., Grossi, F., Puglisi, F., & Aschele, C. (2000) · PubMed · Cited by 57
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy
Wenzel, C., Locker, G. J., Schmidinger, M., et al. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.29879 · Cited by 31
Bajetta, E., Colleoni, M. A., Rosso, R., Sobrero, A. F., Amadori, D., Comella, G., Marangolo, M., Scanni, A., Lorusso, V., Calabresi, F., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90099-2 · Cited by 31
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Prado, C. M. M., Baracos, V. E., McCargar, L. J., Reiman, T., Mourtzakis, M., Tonkin, K., Mackey, J. R., Koski, S., Pituskin, E., & Sawyer, M. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2242 · Cited by 1,104
Metadata
- Authors
- Walko, C. M., & Lindley, C.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2005-01
- Volume
- 27
- Issue
- 1
- Pages
- 23-44
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2087675944
- Cited by
- 659
- References
- 43
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.